Curated News
By: NewsRamp Editorial Staff
March 09, 2026
NeuroOne Hits Record Procedure Volume, Advances in $1B+ Pain & Brain Markets
TLDR
- NeuroOne's FDA-cleared OneRF system achieved record procedure volume, positioning the company to capture billion-dollar markets in drug delivery, BVNA, and spinal cord stimulation ahead of competitors.
- NeuroOne leverages its FDA-cleared electrode platform to develop new products efficiently, with four clearances secured and pipeline programs advancing through strategic partnerships and capital-efficient development.
- NeuroOne's technology has restored a pianist's career and eliminated seizures for a teenager, demonstrating life-changing improvements for patients suffering from severe neurological disorders and chronic pain conditions.
- NeuroOne's thin-film paddle electrode allows pain doctors to perform spinal cord stimulation percutaneously, potentially expanding treatment access beyond traditional surgical implantation methods.
Impact - Why it Matters
This news matters because NeuroOne's medical technology addresses some of the most debilitating neurological conditions affecting millions worldwide, including epilepsy, trigeminal neuralgia (often called 'the suicide disease' due to its severity), and aggressive brain cancers. Their minimally invasive approaches could revolutionize treatment paradigms by reducing hospitalizations, lowering healthcare costs, and improving patient quality of life. The company's progress in billion-dollar markets like chronic pain management and targeted drug delivery represents potential breakthroughs where current treatments often fall short. For investors, NeuroOne's growing commercial traction, strategic partnerships with industry leaders like Zimmer Biomet, and capital-efficient platform approach demonstrate a viable path to addressing massive unmet medical needs while creating shareholder value.
Summary
NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) is demonstrating significant commercial momentum in fiscal 2026, led by CEO Dave Rosa, with record procedure volume for its OneRF® ablation system and promising early success in treating trigeminal neuralgia. The company's technology platform is advancing across three major market opportunities—brain disorders, pain management, and advanced drug delivery—each representing potential billion-dollar markets. Key milestones include FDA 510(k) clearances, a strategic partnership with Zimmer Biomet for brain ablation distribution, and progress toward commercial readiness for drug delivery systems targeting aggressive brain cancers like glioblastoma.
The company reported transformational patient outcomes, including a professional pianist from Chicago who resumed his career after treatment and a teenage girl who became seizure-free after suffering nightly seizures. All nine initial trigeminal neuralgia patients treated are reportedly pain-free, validating the technology's effectiveness. NeuroOne is strategically positioning itself in large addressable markets, noting Boston Scientific's $850 million acquisition of Relievant Medsystems as validation for the basivertebral nerve ablation (BVNA) space. The company is leveraging its existing FDA-cleared technology to develop competitive products for BVNA, drug delivery, and spinal cord stimulation markets.
Financially, NeuroOne guides to at least $10.5 million in product revenue for fiscal 2026, maintains zero debt with $3.6 million in cash, and seeks shareholder approval for a reverse stock split to maintain Nasdaq compliance. The company has four FDA clearances, a growing intellectual property portfolio, and active discussions with potential strategic partners that could generate non-dilutive cash. Leadership strengthened with David Wambeke's appointment as Chief Business Officer, who purchased 1,000,000 shares to demonstrate alignment with shareholders. NeuroOne invites investors to a Virtual Investor Webinar on March 12, 2026, to discuss these developments further.
Source Statement
This curated news summary relied on content disributed by NewMediaWire. Read the original source here, NeuroOne Hits Record Procedure Volume, Advances in $1B+ Pain & Brain Markets
